Search

Rationale and Objectives: We studied hepatosplenic enhancement in rhesus monkeys for 5 hr after rapid administration of perflubron (perfluorooctyl bromide [PFOB]) in an attempt to determine a clinically useful imaging window., Methods: Five rhesus monkeys were examined using perflubron emulsion, 90% w/v perfluorochemical administered intravenously at a dose of 1.5 ml/kg and rate of 0.5 ml/sec. Helical computed tomography examination of the abdomen was obtained prior to the contrast bolus and 5 min, 30 min, 1, 2, 3, 4, and 5 hr postcontrast. Mean density of liver, spleen, and aorta was measured at each time interval., Results: Significant aortic enhancement of 53 +/- 7 Hounsfield units (HU) (p < .0001) and liver enhancement of 19 +/- 4 H (p < .0004) occurred after 5 min and did not change significantly (p > .05) over 5 hr. Splenic enhancement of 35 +/- 9 HU was significant at 5 min (p < .0001) and continued to increase for 5 hr., Conclusion: Enhancement of the liver, blood vessels, and spleen is rapid and persists for at least 5 hr, which suggests a wider temporal window for hepatosplenic imaging with perflubron than is currently available with iodinated contrast agents.

Objective: Because of pending efforts to reform health care in the United States, judicious use of low-osmolality contrast media is important. We studied the effects of using various concentrations and volumes of iohexol, compared with the conventional dose and concentration of diatrizoate meglumine used for CT, to determine if a more cost-effective dose results in diagnostically efficacious liver enhancement., Subjects and Methods: A total of 902 patients received one of nine different doses of IV contrast media. Eight doses of iohexol were used: 125 ml of iohexol 350 (350 mg l/ml, 44 g l/dose), 100 ml of iohexol 350 (35 g l/dose), 150 ml of iohexol 300 (300 mg l/ml, 45 g l/dose), 120 ml of iohexol 300 (36 g l/dose), 100 ml of iohexol 300 (30 g l/dose), 175 ml of iohexol 240 (240 mg l/ml, 42 g l/dose), 150 ml of iohexol 240 (36 g l/dose), and 125 ml of iohexol 240 (30 g l/dose). A single dose (150 ml) of diatrizoate meglumine 60% (w/v) was used (42 g l/dose). Contrast material was injected at a rate of 2 ml/sec. Scanning began 35-45 sec after injection. Quantitative analysis of enhancement was performed by obtaining region-of-interest measurements through the liver on scans obtained before and after injection of contrast material. Mean and maximum changes in hepatic density and mean time to maximum enhancement were measured. Mean time-density curves were subsequently derived for each dose of contrast material. Qualitative analysis of enhancement was performed by using subjective, previously defined criteria. All studies were interpreted in a double-blind fashion., Results: Mean hepatic enhancement was greater with 125 ml of iohexol 350 and 150 ml of iohexol 300 than with other doses of contrast material (p < .05). Both 125 ml of iohexol 350 and 150 ml of iohexol 300 produced actual hepatic enhancement of more than 50 H for over 60 sec. The greatest maximum increase in hepatic density occurred with 125 ml of iohexol 350. When analyzed qualitatively, 150 ml of iohexol 300 resulted in the highest percentage of optimum enhancement., Conclusion: According to quantitative analysis, 125 ml of iohexol 350 administered at a rate of 2 ml/sec produces the best enhancement, whereas according to qualitative analysis, 150 ml of iohexol 300 produces the best enhancement. All doses of iohexol 240 provide poor enhancement compared with a conventional dose of contrast material of 150 ml of diatrizoate meglumine 60% or 150 ml of iohexol 300. A moderate cost savings can be achieved by using 125 ml of iohexol 350 for dynamic sequential CT.

Objective: Spiral CT allows rapid hepatic imaging during a single breath-hold. The increase in imaging speed potentially allows contrast material to be used more efficaciously than with conventional dynamic CT, perhaps allowing a decrease in the volume of required contrast agent. To determine how this can be accomplished, we studied the effect of different bolus IV injection rates and amounts of contrast material on early hepatic enhancement during dynamic bolus spiral CT., Subjects and Methods: A group of 20 healthy male volunteers were divided into four groups of five each. The groups received 75, 100, 125, or 150 ml of contrast material (Omnipaque 300, 300 mg l/ml). Each person within each group was scanned as contrast material was injected at rates of 3, 4, and 5 ml/sec. Hepatic enhancement was evaluated by comparing quantitative regions of interest before and after bolus injection of contrast material. Variations in enhancement produced by changes in volume and injection rate of contrast material were evaluated on early, middle, and late sections of the spiral, corresponding to 32-34, 41-43, and 51-53 sec, respectively, after the injection of contrast material was begun., Results: Hepatic enhancement increased more rapidly when the bolus of contrast material was given at a rate of 5 ml/sec than at the slower rates of 3 or 4 ml/sec. Enhancement of the liver was greatest at the late portion of the spiral (51-53 sec after start of the bolus injection), averaging 73 and 79 H for volumes of 125 and 150 ml, respectively, at 5 ml/sec, and the enhancement was still increasing at that time. Enhancement curves predict 50- and 70-H mean increases in hepatic attenuation on initial slices with scan delays of approximately 40 and 50 sec, respectively, for these two protocols., Conclusion: Our results demonstrate that there is a marked dependence on early hepatic enhancement produced by variations in volume and injection rate of contrast material. We found no difference in the results produced by 125- and 150-ml volumes. These results are important for maximizing the effectiveness of IV contrast material during rapid hepatic spiral CT scanning.

The enhancement characteristics of the liver and spleen produced by a hepatocyte-specific magnetic resonance imaging agent, an arabinogalactan-coated ultrasmall superparamagnetic iron oxide derivative, BMS 180550, were evaluated. Both heavily T1- and T2-weighted sequences were used. Imaging was performed in the farm pig model, as a function of contrast agent concentration (5, 10, and 20 mumol of iron per kilogram) and delay (immediate, 0.5, 2.5, 5.0, 7.5, and 9.0 hours) after bolus injection of BMS 180550. BMS 180550 provided excellent contrast enhancement characteristics by producing marked positive enhancement with T1-weighted sequences and marked negative enhancement with T2-weighted sequences. The T1-weighted enhancement immediately after contrast agent injection was of greater magnitude in the spleen (329% +/- 83) than in the liver (66% +/- 16). Postcontrast negative enhancement with T2-weighted sequences was largely hepatocyte specific at 5 and 10 mumol/kg but was also seen within the spleen at 20 mumol/kg. The authors discuss the possible mechanisms that produce these changes and conclude that 10 mumol/kg BMS 180550 is near the optimum dose for maximizing the enhancement properties of this agent with all sequences in the farm pig.

Ninety-six patients with known or suspected focal hepatic disease were evaluated in a multiinstitutional study of manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'bis(phosphate) (DPDP) as a hepatic-specific contrast agent for magnetic resonance (MR) imaging. The patients were divided into four dose groups, receiving 3, 5, 8, or 10 mol/kg of Mn-DPDP. Half of the patients in each dose group received Mn-DPDP as an intravenous bolus (0.25 mL/sec) and the other half as an infusion (1 mL/min). Patients were evaluated with T1-weighted imaging parameters. No serious side effects were noted. In 76 patients, both Mn-DPDP-enhanced and nonenhanced T1-weighted images depicted the same number of lesions, but one additional lesion was depicted with enhanced imaging in 12 patients, two additional lesions in three patients, and three additional lesions in three patients. Enhanced, T1-weighted images depicted no more lesions than nonenhanced, T2-weighted images in 77 patients, but one more lesion was depicted in nine patients, two more lesions in two patients, three more lesions in one patient, and four more lesions in one patient.

The purpose of our study was to determine the frequency of detection of small hepatic lesions (less than or equal to 15 mm) in outpatients who had abdominal CT and to assess the significance of these lesions in the presence or absence of known malignant tumors. Contrast-enhanced abdominal CT scans in 1454 patients were reviewed. In 254 patients (17%), hepatic lesions 15 mm or smaller were detected. In 51% of these patients, lesions were judged benign on the basis of other imaging studies, biopsy results, or stability for at least 6 months as shown by CT. Lesions were judged malignant on the basis of progression seen on radiologic studies or biopsy in 22%. The other 27% of the patients had lesions that could not be classified. The majority of patients with small hepatic lesions (82%) were known to have a malignant tumor; in 51% of these patients, lesions were diagnosed as benign. No patient without a known malignant tumor had a small hepatic lesion that was determined to be malignant. Multiple small lesions were more likely to represent malignant disease than were single small lesions. We conclude that small hepatic lesions are common (seen in 17% of our patients), and that there is a high probability that hepatic lesions smaller than 15 mm are benign, even in patients known to have an extrahepatic malignant tumor.

Fifty computed tomographic (CT) arterial portography (CTAP) examinations were retrospectively reviewed to determine the prevalence of a pseudolesion, defined as a focal low-attenuation area located in the medial segment of the left hepatic lobe immediately anterior to the porta hepatis. This pseudolesion was considered to be present if the described low-attenuation area was detected with CTAP but was not confirmed with one or more of the following: delayed-iodine hepatic CT (DICT), magnetic resonance (MR) imaging, surgery, and routine follow-up abdominal CT. A pseudolesion was suspected in seven of 50 (14%) cases. Correlation was made with findings at DICT in all seven cases and at MR imaging in five of the seven cases. In addition, correlation with findings at pathologic examination was made in four of the seven cases (57%). Correlation with findings on one or more follow-up abdominal CT scans was also made in three of the seven cases.

We used an animal model to investigate the hepatic enhancement characteristics of manganese dipyridoxyl diphosphate (MnDPDP) related to time, dose, and pulse sequence. The contrast doses selected were in the human tolerance range. Using an SE 300/15 pulse sequence, maximum mean hepatic enhancement of 45% (8 mumols/kg) and 58% (12 mumols/kg) over baseline was seen during a plateau maintained between 5 and 50 minutes postinjection in the 8 mumols/kg group, and between 10 and 90 minutes in the 12 mumols/kg group. This plateau was followed by a very gradual decline in hepatic enhancement. Using either 4 or 8 mumols/kg, there was a significant increase in postcontrast hepatic intensity on all relatively T1-weighted pulse sequences (spin echo [SE] 300/15, inversion recovery [IR] 1400/20/400, gradient echo [GE] 47/13/80 degrees, and GE 60/20/30 degrees) except GE 47/13/80 degrees at 4 mumols/kg. At 8 mumols/kg there was superior enhancement, with IR 1400/20/400 and SE 300/15, but at 4 mumols/kg there was no consistently superior sequence. None of the relatively T2-weighted pulse sequences (SE 2000/50, SE 2000/100, or GE 100/30/20 degrees) demonstrated a significant change in hepatic intensity using either dose of contrast. The data suggest that the best combination of dose, pulse sequence, and time for hepatic imaging with MnDPDP is 8 mumols/kg using heavily T1-weighted sequences 5 to 60 minutes following contrast administration.

The authors evaluated the safety and efficacy of a biopsy gun for performance of image-guided percutaneous biopsy of hepatic allografts in liver transplant recipients. Two hundred fifty-two liver biopsies were performed in 58 transplant recipients over a 27-month period by using this instrument with an 18-gauge needle. Major complications occurred in two of the 252 biopsies (0.8%): One hemopneumothorax necessitated drainage with a chest tube, and one hemorrhage necessitated transfusion. No patient required surgical exploration because of a complication of the biopsy. Specimens were adequate for accurate histopathologic diagnosis in 248 of 252 procedures (98.4%). The authors conclude that image-guided percutaneous biopsy of hepatic allografts with use of the biopsy gun is a safe and accurate method of obtaining hepatic tissue from liver transplant recipients for histopathologic analysis.

The enhancement characteristics in different portions of the liver during dynamic sequential bolus computed tomography (CT) with iodinated contrast material (DSBCT) were prospectively evaluated in 75 patients by using iothalamate meglumine, iopamidol, and iohexol (25 patients received each agent). After baseline noncontrast CT was performed, DSBCT was performed with a 180-mL intravenous bolus administered at 2 mL/sec. Scanning was started 25 seconds after the bolus was initiated, by using a 3-second scan time and rapid cephalocaudal table incrementation, yielding contiguous 8-mm-thick sections at a rate of nine sections per minute. On postcontrast images, peak enhancement was 115% for iopamidol and 117% for iohexol, both of which were superior to iothalamate meglumine at 95% (P less than .05). After peaking, enhancement then decreased for all three contrast agents, although the decline was more precipitous for iothalamate meglumine. Enhancement on the more caudal sections with both iopamidol and iohexol was superior to that with iothalamate meglumine (P less than .05). The data suggest that the enhancement characteristics for the two nonionic agents may be more optimal for detection of focal hepatic lesions than the ionic agent.

With a recently described rat model technique for direct hepatic injection of tumor cells for imaging research, there were concerns that the injection itself might produce lesions detectable with magnetic resonance (MR) imaging, thereby producing false-positive results. To examine this possibility, the authors prospectively studied 14 Sprague-Dawley rats after direct hepatic injection of cells from a rat hepatoma cell line. The rats were imaged with a variety of pulse sequences before and after intravenous injection of the contrast agent manganese dipyridoxal diphosphate at a dose of 8 mumol/kg. No intrahepatic lesions could be detected with MR imaging during the first 6 days after direct hepatic injection of the tumor cells. Therefore, the direct injection technique should be accurate for evaluating various MR imaging sequences and contrast agents for early hepatic tumor detection.

Surgical treatment has proved to be of benefit to patients with primary and metastatic tumors of the liver. However, the ability to localize tumors preoperatively to particular segments within the liver has not been emphasized. The large size of this organ and its complex vascular structure have not allowed the surgeon either to determine accurately the hepatic segment occupied by the tumor or to identify major vascular structures adjacent to the tumor. We have expanded the use of a new roentgenologic technique to determine preoperatively with more clear definition the segmental anatomy of the liver. Computerized tomographic portography (CT-P) images hepatic veins and the segmental branches of portal vein and identifies the anatomic location of tumor nodules. To read the roentgenograms, one first identifies the middle CT-P slice that will cut the transverse scissura. Slices cephalad to the transverse scissura are through segments 7, 8, 4a and 2 in a clockwise order; slices caudad to the transverse scissura are through 6, 5, 4b and 3. Selected CT-P cuts from a series of patients show the typical CT-P configuration of the hepatic vasculature anatomy and the structures that can be identified roentgenologically. The CT-P provides valuable information not previously available preoperatively to the surgeon operating upon the liver.

The authors retrospectively studied 36 hepatic masses in 20 patients who underwent computed tomography during arterial portography (CTAP) and subsequent hepatic tumor resection. The authors used the right main and left main portal veins as landmarks for the transverse scissura, along with the hepatic veins, the gallbladder fossa, and the umbilical fissure to blindly predict the segmental location of each tumor confirmed at surgery. The right main and left main portal veins were found to be consistently near the middle sections through the liver. CTAP findings and surgical descriptions agreed on the primary segmental location of 33 of 36 focal lesions (92%) but disagreed on the extent of 11 of 36 lesions (31%). Further review of the CTAP scans of the 11 lesions revealed that the extent of the lesion was more correctly described at surgery in six masses and at CTAP in four masses; in one lesion, opposite margins of the same mass were correctly described at both surgery and CTAP. Since it may be difficult or impossible to localize deep hepatic lesions intraoperatively by means of palpation or inspection, CTAP is a helpful preoperative tool for determining the segmental location of lesions and for planning the surgical approach.

Hepatic MRI has become a useful imaging modality in recent years. As with all diagnostic imaging, the scanning techniques available for hepatic MRI are manifold and complex. The article discusses these techniques and their practical applications. Contrast agents and the MR appearances of various pathologic hepatic entities are also reviewed.

Computed tomography of 75 biopsy proven cirrhotic patients was analyzed volumetrically and compared with CT on 50 normal subjects in an attempt to quantitate hepatic morphologic changes specific for cirrhosis. Our data show that the mean percentage of the total liver volume occupied by the right hepatic lobe decreased by 15.2% (p less than 0.0001) and the mean percentage of the total liver volume occupied by the medial segment of the left lobe decreased in volume by 10.9% (p less than 0.09) when compared with normals. Concomitantly, the mean percentage of the total liver volume occupied by the caudate lobe increased by 192% (p less than 0.0001) and the mean percentage of the total liver volume occupied by the lateral segment of the left lobe increased by 55.6% (p less than 0.0001). This increase in the volume of the lateral segment of the left lobe and decrease in the volume of the medial segment of the left lobe have not been described previously. The cirrhotic patients were divided according to etiology of their disease: alcoholic or nonalcoholic. No statistically significant difference was found in the morphologic changes based on etiology when the data were examined using analysis of variants.

We conducted a randomized, blinded, prospective study evaluating hepatic parenchymal density changes during dynamic bolus CT (180 ml of contrast material given IV) and delayed CT (5 hr after 60 g of iodine) in order to compare the enhancement characteristics of an ionic contrast agent (iothalamate-60) and two nonionic agents (iohexol-300 and iopamidol-300). A total of 75 patients with known or suspected cancer were studied (25 patients per contrast agent). After a baseline unenhanced CT scan was obtained, dynamic bolus and delayed CT scans were obtained for all patients with one of the three contrast agents. The density of the liver and spleen was measured in Hounsfield units (H) for unenhanced CT, dynamic bolus CT, and delayed CT. The average percentage of enhancement was calculated as follows: postcontrast density minus precontrast density was divided by precontrast density and then multiplied by 100. For dynamic bolus CT, the average percentage of enhancement of the liver was 105% when iohexol-300 was used, 98% when iopamidol-300 was used, and 83% when iothalamate-60 was used. No significant difference was seen between the postcontrast enhancement of the three contrast agents on dynamic bolus CT scans (p greater than .05). For delayed CT, the average percentage of enhancement of the liver was 34% when iothalamate-60 was used, 28% when iopamidol-300 was used, and 16% when iohexol-300 was used. Both iothalamate-60 and iopamidol-300 showed superior enhancement on delayed CT, compared with iohexol-300 (p = .0001). We conclude that for dynamic bolus CT, all three contrast agents are similar, with no statistically significant differences in postcontrast enhancement of the liver. For delayed CT, however, hepatic enhancement with iothalamate-60 and iopamidol-300 is statistically superior to that with iohexol-300.

Twenty-one human hepatic liver biopsy samples were evaluated by nuclear magnetic resonance spectroscopy. This spectroscopy was performed by obtaining multiple and not single T2 values (T2-long and T2-short). Neoplastic tissue had greater T2-long and T2-short values than diffuse liver disease. The T2-short correlated, r = 0.947 (p less than 0.01), with the percentage of cancer cellularity within the tissue specimens. There was no correlation between the multiple T2 values and the degree of fibrosis and inflammation. Minimal correlation was noted between the T2-long and percentage of fat within the diffuse disease (cirrhotic) specimens, r = 0.636 (p less than 0.05). The possible reasons for the above findings are discussed.

A technique for computed tomography directed percutaneous liver biopsy using small gauge (18-20) needles is described. In 51 procedures performed on 50 patients tissue specimens adequate for diagnosis were obtained 49 times (96%). There was one false negative diagnosis. The correct diagnosis was made in 48 of 51 (94%) procedures on 48 of 50 (96%) patients. There were no significant complications.

Pancreatic neoplasms often present with hepatic lesions as well as a pancreatic mass, as seen on abdominal computed tomography examination. To obtain histologic diagnosis, we advocate computed tomography-directed biopsy of the liver lesion instead of the pancreatic mass because of the increased accuracy and safety of hepatic biopsy as compared with pancreatic biopsy.

The presence of ascites has been considered a contraindication to percutaneous biopsy of the liver. To determine the validity of this assumption, we performed percutaneous biopsies of the liver under CT or sonographic guidance in 28 patients who had ascites and in 28 patients who did not have ascites and compared the complication rates in the two groups. Twenty-two patients (79%) in the group with ascites and 19 patients (68%) in the group without ascites had biopsies to determine the cause or extent of chronic liver disease. The remainder were oncologic patients who had biopsies to determine the cause of a focal hepatic mass. The complication rate in the patients who had ascites (32%) was less than that in the patients who did not have ascites (43%) (the difference did not reach statistical significance, p less than .30). In the ascites group, complications included transient hypotension (five patients), a mild-to-moderate fall in hematocrit (three patients), and a small leak of ascites from the biopsy site (one patient). In the control group, minor complications included transient hypotension (three patients), a mild-to-moderate fall in hematocrit (seven patients), and a small subcapsular hematoma (one patient). One major complication occurred in the control group: a patient required a blood transfusion because of the fall in his hematocrit. We conclude that the complication rate in liver biopsies guided by CT or sonography in the presence of ascites is not higher than similar biopsies done in the absence of ascites. Ascites should not be considered a contraindication for performing such biopsies.

In an effort to determine whether T2 values of liver and muscle change with increasing field strength, 144 abdominal MR examinations were retrospectively evaluated. These patients were evaluated with a dual echo T2-weighted spin-echo sequence. Eighty-two of the examinations were performed at 0.5 Tesla and 72 at 1.5 Tesla (T). Eleven of the patients were evaluated with both MR systems with the same sequences. T2 values were also obtained from a Fe NH4(SO4)2 12H2O phantom. The T2 values of liver decreased from 57.8 +/- 11.3 at 0.5 T to 43.7 +/- 8.3 at 1.5 T. The T2 values of muscle decreased from 44.2 +/- 9 at 0.5 T to 35.4 +/- 7.2 at 1.5 T. Patients who were examined on both systems also demonstrated a decrease in both liver and muscle T2 values. For concentrations in the range of hepatic T2's, the phantom demonstrated a decrease in T2 values from 0.5 to 1.5 T ranging from 20.3 to 23.4%. All the T2 changes were statistically significant (p less than .05). The findings suggest that T2 values may depend on field strength, or may vary due to other hardware-related differences.

Magnetic resonance imaging of the liver was performed on 11 rabbits (3-5 kg) before and at 4, 5 and 6 hours after the intravenous administration of 0.3 mM/kg Gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) to determine if hepatocytes exhibit delayed excretion of Gd-DTPA, similar to the delayed hepatic excretion of iodinated contrast agents. Imaging was performed at 0.5 Tesla in the axial plane using a spin echo sequence of TR/TE, 250/20 milliseconds. Precontrast and postcontrast intensity changes for liver and muscle were standardized and compared over time. The average percent of postcontrast enhancement for liver and muscle, respectively was: 30.6 +/- 9.5% and 17.3 +/- 17.0% immediately postcontrast; 9.7 +/- 13.6% and 1.6 +/- 13.8% at 4 hours; 9.6 +/- 7.8% and 4.3 +/- 13.2% at 5 hours; and 11.0 +/- 7.8% and 4.1 +/- 11.7% at 6 hours. We conclude that there is not significant hepatocyte excretion of Gd-DTPA at 4 to 6 hours postcontrast injection in rabbits and that this may not be an advantageous paramagnetic contrast strategy for focal hepatic lesion detection.

Five patients with known primary malignancy demonstrated fatty infiltration of the liver on routine computed tomography (CT) examination. Within the diffuse fatty infiltration were focal areas of relatively increased beam attenuation in four cases. These areas of increased beam attenuation are nonspecific as to etiology. Their differential diagnosis is discussed. Since the true extent of the neoplastic process may be underestimated by conventional CT and celiac angiography, superselective angiography, computed angiotomography, or biopsy is required to accurately assess the etiology and the extent of the disease.

During the 3-year period from May 1981 to June 1984, 145 patients with hepatic abnormalities demonstrated by computed tomography (CT) or ultrasonography (US) underwent 151 imaging guided percutaneous hepatic biopsies. These biopsies were performed with needles ranging in size from 21-gauge aspiration to 14-gauge cutting type. Histologic and cytologic results were correlated with subsequent surgical, autopsy, and clinical follow-ups ranging from 2 months to 3 years. The overall accuracy for imaging-guided biopsies was 92.1% and 98% for diagnosis of malignant lesions. Our complication rate of 1.3% is comparable to that reported in other studies. We discuss indications, techniques, and risks for imaging-guided percutaneous hepatic biopsy.

Sixty patients underwent CT scanning of the liver prior to, immediately after, and four hours after intravenous administration of 60% meglumine diatrizoate. Twenty patients received a 50 ml bolus of contrast material (14.6 g of iodine), 20 received 100 ml (29.2 g of iodine), and 20 received 200 ml (58.4 g of iodine). In each group, delayed CT scanning safely raised the inherent density of the liver significantly (increase of 14.3% using 50 ml; 23.9% using 100 ml; and 40.7% using 200 ml). Thus, delayed scanning with doses presently used in abdominal and neurological CT examinations may be helpful in detecting hepatic lesions.